What We Do
Detection of infectious diseases in the field just got easier. A closed-system requiring minimal resources can identify leishmaniasis and soon other infectious diseases with unprecedented mobility. This first of its kind diagnostics toolset will revolutionize field work.
The Product
- [PROTOTYPE] In-field target specific process stage consumable for infectious disease testing using isothermal amplification techniques
- [IDEATION] Expand testing panel to additional infectious and non-infectious diseases using DNA targets
- [IDEATION] Expand tests to include RNA virus detection
Target Customer Pain Points
- High fidelity diagnostics are hard to come by in the field
- Contamination of samples decreases confidence in results
- Consistent power sources, equipment repair costs, and transport/ logistics
challenges have inhibited use of sophisticated lab equipment - The US Army, Medical Facilities in underserved areas, and Global Health Initiatives can take advantage of easy-to-use, low cost solutions
Differentiation
- Closed-system decreases contamination risk for the patient sample and minimizes clinician/technician exposure to infectious agents
- Designed specifically for resource-limited environments.
- Improved sample stabilization within the closed and field-ready system
Market Size
The global market for infectious disease diagnostics alone is projected to reach $18 billion by 2019, a CAGR of 7.9%. More specifically, the Rapid Diagnostic Test (RDT) market is expected to grow at a CAGR of 4.1%
Progress & Milestones
- Multi-generation prototypes tested and validated
- Continue benchmark testing against current “gold standards” such as PCR
- Continue clinical validation to substantiate results relative to other closest
“competitors” - Identify manufacturers to produce and scale field-ready materials
Management Team
- Peter Melby, PhD
- Bruno Travi, PhD
- Alexander Vo, PhD
- Scott Moen, PhD
Download this document